NYMX - farmaco cancro prostata

Adsx ha scritto:
Meglio CHINA INDEX RUNNING sei sempre di corsa :clap: :clap: :clap:


azz quest'anno invece al Nostradamus son na pippa..... :D :D :D :D



Va bè ora stacco baracca...mi guardo LOST su RAI 2 :D :D :D :clap: :clap: :clap: :clap:

A presto Gian!
Ciao Grec!

:yes: OK!
 
Adsx ha scritto:
Io nn mi metto proprio x adesso. PASSO, alla prossima mano.


tanto è ripartita :D :D :D 5.70 ora ....


mi dedico al film prima di rovinarmi il GURRIGULUM giornaliero :D :D :D
 
Mr China Investiment ha scritto:
azz quest'anno invece al Nostradamus son na pippa..... :D :D :D :D



Va bè ora stacco baracca...mi guardo LOST su RAI 2 :D :D :D :clap: :clap: :clap: :clap:

A presto Gian!
Ciao Grec!

:yes: OK!

Avrai altri impegni e nn ti dedichi con il massimo impegno al nostradamus.
E poi siamo all'inizio.
Ciaoooooo
 
Mr China Investiment ha scritto:
su NYMX ora ci andrei cauto....

guarda su YAHOO FORUM...dopo averla super pompata la stanno da due tre minuti "bruciando"

mi metto vicino ai 5 :D


5.32 ora :D
 
Mr China Investiment ha scritto:
close 4.71

oggi proverò fra 3.95 e 4.05

:yes:


azzzzzzzzzzzzz che coraggio china ! ma le hai prese quando stavano a 2$ ??? possibile che mai nessuno me le segnali sto cose ???? egoist ! egoist ! :'(
 

Allegati

  • Anonimo.gif
    Anonimo.gif
    9 KB · Visite: 136
una delle 3 ipotesi.. ;)
 

Allegati

  • nymx.png
    nymx.png
    19,5 KB · Visite: 112
magari sbaglio ma una piccola trance a 4.10 la ho presa.....

incrementerò poi su eventuali rotture rialziste....
 
dimenticavo


il motivo è questo


Nymox to Present at Dutton Associates' ''Recognizing Opportunity'' SmallCap Conference in San Francisco Mar. 28
Wednesday March 22, 9:30 am ET


HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--March 22, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) will present at Dutton Associates' "Recognizing Opportunity" SmallCap Conference. Nymox along with a select group of emerging growth companies in a variety of sectors, including energy, alternative energy, technology, security, financial services, and consumer products, will update investment professionals on business activities, trends and current developments.
ADVERTISEMENT


The conference will take place at St. Regis Hotel in San Francisco on Tuesday, March 28 from 7:45 a.m. to 5 p.m. The Company will make a presentation in the morning. In the afternoon, Nymox will present to small, informal groups of investment professionals during two break-out sessions. For more conference information and registration, visit www.jmdutton.com.

Nymox Pharmaceutical Corporation is engaged in development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is conducting pivotal Phase II clinical trials for NX-1207 a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. Nymox offers AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease.

About Dutton Associates

Dutton Associates, an international issuer-paid equity research firm, offers independent, fundamental research on over 120 small cap public companies. The company's 29 analysts are primarily CFA charterholders with, on average, over 20 years of experience at the major securities firms. For more information, visit www.jmdutton.com.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.



Contact:
Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
www.nymox.com

--------------------------------------------------------------------------------
Source: Nymox Pharmaceutical Corporation
 
sbagliero' ma secondo me questo sara' uno dei migliori titoli del 2006 nonostante il rialzo che gia' c' è stato
 
osinod ha scritto:
sbagliero' ma secondo me questo sara' uno dei migliori titoli del 2006 nonostante il rialzo che gia' c' è stato



mi hai preceduto di un secondo.... :clap: OK! OK!

stavo per scrivere ottimo close.... :D :D :D :D :D
 
Nymox Reports 2005 Financial Results
Wednesday March 15, 9:00 am ET
Product Sales Increase by 32%


HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--March 15, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) announced today its financial results for the year ended December 31, 2005. Product sales increased by 32% and amounted to $424,506 for 2005, compared to $321,895 for 2004. Nymox currently has $11.9 million in financing available from its most recent October 21, 2005 financing. Nymox reported a net loss of $3,584,528, or $0.14 per share, compared to $3,745,625, or $0.15 per share for 2004. The weighted, diluted average number of common shares at December 31, 2005 was 26,103,704, compared to 25,103,252 at December 31, 2004.
ADVERTISEMENT


"The Company had a highly productive year in which many solid milestones were made, while our burn rate was again minimal by industry standards", said Paul Averback, CEO and President of Nymox.

Nymox Pharmaceutical Corporation is a biopharmaceutical company with three unique proprietary products on the market, and a significant R&D pipeline of drug products in development. Nymox is developing NX-1207, a novel treatment for benign prostatic hyperplasia. NX-1207 has shown statistically significant positive results in Phase 1 and 2 clinical trials in the U.S. and is currently in pivotal late stage Phase 2 human testing in the US. Nymox has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company is developing a new treatment for E. coli O157:H7 contamination in food products. Nymox has NXD-2858 and NXD-9062 which are under development as drug treatments aimed at the causes of Alzheimer's disease, and has several other drug candidates in development. Nymox developed and is currently offering its AlzheimAlert(TM) test, a nationally certified clinical reference laboratory urinary test that is the world's only accurate, non-invasive aid in the diagnosis of Alzheimer's disease. The AlzheimAlert(TM) test is certified with a CE Mark, making the device eligible for sale in the European Union. Nymox has signed distribution deals for AlzheimAlert(TM) with several companies in Europe. Nymox also developed and markets NicAlert(TM) and TobacAlert(TM); tests that use urine or saliva to detect use of and exposure to tobacco products. NicAlert(TM) has received clearance from the U.S. Food and Drug Administration (FDA) and is also certified with a CE Mark in Europe. TobacAlert(TM) is the first test of its kind to accurately measure second hand smoke exposure in individuals.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities
 
OCIO A DOMANI

Nymox to Present at Dutton Associates' ''Recognizing Opportunity'' SmallCap Conference in San Francisco Mar. 28
Wednesday March 22, 9:30 am ET


HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--March 22, 2006--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) will present at Dutton Associates' "Recognizing Opportunity" SmallCap Conference. Nymox along with a select group of emerging growth companies in a variety of sectors, including energy, alternative energy, technology, security, financial services, and consumer products, will update investment professionals on business activities, trends and current developments.
ADVERTISEMENT


The conference will take place at St. Regis Hotel in San Francisco on Tuesday, March 28 from 7:45 a.m. to 5 p.m. The Company will make a presentation in the morning. In the afternoon, Nymox will present to small, informal groups of investment professionals during two break-out sessions. For more conference information and registration, visit www.jmdutton.com.

Nymox Pharmaceutical Corporation is engaged in development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is conducting pivotal Phase II clinical trials for NX-1207 a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. Nymox offers AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease.

About Dutton Associates

Dutton Associates, an international issuer-paid equity research firm, offers independent, fundamental research on over 120 small cap public companies. The company's 29 analysts are primarily CFA charterholders with, on average, over 20 years of experience at the major securities firms. For more information, visit www.jmdutton.com.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
 
Indietro